A Novel Approach to Treatment Refractory Childhood Obsessive-Compulsive Disorder: D-Cycloserine Augmented Behaviour Therapy

Phase 2

Completed

• Conditions: Pediatric Obsessive-Compulsive Disorder; Mental Health - Other mental health disorders

• Registration Number: ACTRN12609000370202
• Lead Sponsor: Dr Lara Farrell

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-05-27
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

1. primary diagnosis of OCD with score of at least 19 on CYBOCS at pre- (moderate range);
2. child meets treatment resistant criteria;
3. if taking a selective-serotonin reuptake inhibitor (SSRI) medication, dose must be stable for one-month prior to study entry and remain unchanged.

Exclusion Criteria

Exclusion criteria for participation include:
1. organic mental disorder;
2. other medications that are contraindicated with D-Cycloserine (DCS);
3. pregnancy (will be screened for and if sexually active be required to use birth control);
4. psychosis;
5. pervasive developmental disorder;
6. history of seizure;
7. history other serious medical condition that would be contraindicated with DCS (ie., cardiovascular, liver, kidney, respiratory etc);
8. serious suicidal risk;
9. concurrent psychotherapy;
10. current diagnosis of tuberculosis (TB);
11. currently taking medication that lowers seizure threshold (ie., clozapine);
12. impaired intelligence (IQ; likely < 70).

Study & Design

• Study Type: Interventional
• Study Design: Not specified